Medicaid Health Plan 101


(What you always wondered, but never asked)



Locations of Medicaid Health Plans



 There are currently 11 Medicaid Health Plans within the State, and each of the plans service particular prosperity regions which are groups of counties:





- The information in the following slides is from the standard contract template between the State of Michigan and the Medicaid Health Plans in the State.
- Medicaid Health Plans are contracted with the State to provide a set of mutually agreed upon services. The current contract began on January 1. 2016 and expires on December 31st 2020.
- The following populations <u>must</u> enroll in a Medicaid Health Plan: Children in foster care; Families with children receiving assistance under the Financial Independence Program (FIP); Persons enrolled in Children's Special Health Care Services (CSHCS); Persons under age 21 who are receiving Medicaid; Persons Enrolled in the MIChild Program; Persons receiving Medicaid for the aged; Persons receiving Medicaid for the blind or disabled; Persons receiving Medicaid for caretaker relatives and families with dependent children who do not receive FIP; Pregnant women; Medicaid eligible persons enrolled under the Healthy Michigan Plan; Supplemental Security Income (SSI) Beneficiaries who do not receive Medicare.
- The following populations <u>may</u> enroll in a Medicaid Health Plan: Migrants; Native Americans; Persons with both Medicare and Medicaid eligibility.



• The following populations <u>are excluded</u> from enrollment in a Medicaid Health Plan: Children in Child Care Institutions; Deductible clients (also known as Spenddown); Persons without full Medicaid coverage; Persons with Medicaid who reside in an Intermediate Care Facilities for Individuals with Intellectual Disability (ICF/ID) or a State psychiatric hospital; Persons receiving long-term care (custodial care) in a nursing facility; Persons authorized to receive private duty nursing services; Persons being served under the Home & Community Based Elderly Waiver; Persons with commercial HMO/PPO coverage; Persons in PACE (Program for All-inclusive Care for the Elderly); Persons in the Refugee Assistance Program; Persons in the Repatriate Assistance Program; Persons in the Traumatic Brain Injury program; Persons diagnosed with inherited disease of metabolism who are authorized to receive metabolic formula; Persons dis-enrolled due to Special Disenrollment or Medical Exception for the time period covered by the Disenrollment or Medical Exception; Persons residing in a nursing home or enrolled in a hospice program on the effective date of enrollment in the Contractor's plan; Persons incarcerated in a city, county, State, or federal correctional facility; Persons participating in the MI Health Link Demonstration.



- MDHHS contracts with an Enrollment Services Contractor to contact and educate Medicaid beneficiaries regarding managed care and assist beneficiaries to enroll, disenroll, and change enrollment with their health plan.
- MDHHS holds the contract with the Enrollment Services Contractor. The Medicaid Health Plan must work with the Enrollment Services Contractor as directed by MDHHS.
- Enrollment files are sent monthly to the Medicaid Health Plans by the State.
- Beneficiaries who do NOT select a health plan within the allotted time period are automatically assigned to a
 Medicaid Health Plan based on the plan's capacity to accept new Enrollees and performance in areas specified by
 MDHHS (e.g., quality metrics).
- MDHHS will automatically assign a larger proportion of beneficiaries to the highest performing Medicaid Health Plans. Members of a family unit will be assigned together whenever possible.



Enrollment Lock-In and Open Enrollment for Enrollees in Counties Not Covered by Exceptions:

- Enrollment with the Medicaid Health Plan is for a period of 12 months.
- Sixty Days prior to each Enrollee's annual open enrollment period, MDHHS will notify Enrollees of their right to disenroll with their current Health Plan and reenroll with another Health Plan.
- Enrollees will be provided with an opportunity to select any Health Plan approved for their county of residence during the annual open enrollment period.
- Enrollees will be notified that inaction during open enrollment will retain their current Health Plan enrollment.



- Enrollees who choose to remain with the same Health Plan will be deemed to have had their opportunity for disenrollment without cause and declined that opportunity until the next open enrollment period.
- New Enrollees or Enrollees who change from one Health Plan to another will have 90 Days from the enrollment begin date with the Health Plan or during the 90 days following notification of enrollment, whichever is later, to change Health Plans without cause.
- All enrollment changes will be approved and implemented by MDHHS, effective the next available calendar month.
- Enrollees disenrolled from the Health Plan due to loss of Medicaid eligibility or other action will be prospectively reenrolled to the same Health Plan automatically, provided eligibility is regained within two months.



- Health Plan must ensure Enrollees have access to emergency and Urgent Care Services 24 hours per day, 7 days per week. All PCPs within the network must have information on this system and reinforce with their Enrollees the appropriate use of the health care delivery system.
- Health Plan must require that physician office visits be available during regular and scheduled office hours.
- Health Plan must ensure that Enrollees have access to evening and weekend hours of operation in addition to scheduled daytime hours.
- Health Plan must ensure that Network Providers offer hours of operation that are no less than the hours of operation offered to commercial Enrollees, or hours of operation comparable to Medicaid FFS, if the Provider serves only Medicaid Enrollees.
- Health Plan must make available direct contact with a qualified clinical staff person through a toll-free telephone number at all times, 24 hours per day, 7 days per week.



- The PCP is responsible for supervising, coordinating, and providing primary care, initiating referrals for specialty care, maintaining continuity of each Enrollee's health care, and maintaining the Enrollee's medical record, which includes documentation of all services provided by the PCP as well as any specialty or referral services for each assigned Enrollee.
- A PCP may be any of the following: family practice physician, general practice physician, internal medicine physician, OB/GYN specialist, pediatric physician, nurse practitioners, physician assistants, and other physician specialists when appropriate for an Enrollee's health condition.
- The Health Plan must provide all Enrollees the opportunity to select their PCP at the time of enrollment.
- When the Enrollee does not choose a PCP at the time of enrollment, the Health Plan must assign a PCP no later than 30 Days after the effective date of enrollment.



- The Health Plan must provide non-emergent medical transportation (NEMT), including travel expenses, to authorized, covered services.
- The Health Plan's policies must include provisions for the following:
- ❖ Determination of the most appropriate mode of transportation to meet the Enrollee's medical needs, including special transport requirements for Enrollees who are medically fragile or Enrollees with physical/mental challenges, pregnancy status, infancy, need for Enrollee to keep appointments confidential (such as when it is not appropriate for Enrollees to ask neighbors or family members for transportation), additional riders and/or car seats, housing status that affects pick up and drop off locations.
- Prevention of excessive multi-loading of vehicles such that Enrollees are not unduly burdened or forced to travel for significantly longer periods of time than is necessary.



- Scheduling system must be able to schedule Enrollee transportation services in at least three modes:
- On-going prescheduled appointments for at least thirty Days, such as, but not limited to, dialysis, chemotherapy or physical therapy.
- ❖ Regularly scheduled appointments; plans may require reasonable advance notice (e.g. 48 − 72 hours) of the need for transportation.
- Urgently scheduled appointments for which the Enrollee requires transportation on the same day as the request or the following day.
- Method for reimbursing mileage to individuals when it is appropriate for the Enrollee to drive or be driven to an
 Urgent Care facility or emergency department.
- Health plans are working on several initiatives related to health equity, population health, low birth weight, behavioral health integration, and social determinates of health. Health plans also have internal programs such as disease management to work with people who have chronic diseases like asthma.


Characteristics of Medicaid Health Plans: Tobacco Cessation Services



- The Health Plan must not place prior authorization requirements on tobacco cessation treatment or limit the type, duration, or frequency of tobacco cessation treatments.
- The Health Plan must provide tobacco cessation treatment that includes, at a minimum, the following services:
- ❖ Intensive tobacco cessation treatment through an MDHHS-approved telephone quit-line.
- Individual tobacco cessation counseling/coaching in conjunction with tobacco cessation medication or without.
- Non-nicotine prescription medications.
- Prescription inhalers and nasal sprays.
- The following over-the-counter agents: Patch; Gum; Lozenge.
- Combination therapy the use of a combination of medications, including but not limited to the following combinations:
- Long-term (>14 weeks) nicotine patch and other nicotine replacement therapy (gum or nasal spray).
- Nicotine patch and inhaler.
- Nicotine patch and bupropion SR.


Characteristics Of Medicaid Health Plans: Tobacco Cessation Services Grid





Characteristics Of Medicaid Health Plans: Tobacco Cessation Services Grid (Cont.)





https://www.michigan.gov/documents/mdch/MichiganMedicaidTobaccoCessationBenefits_477848_7.pdf



- HEDIS is a term that started in the 1980's and began with a group of employers and quality experts. It was shifted to NCQA (National Committee for Quality Assurance) as a tool in the early 1990's.
- NCQA was founded in 1990 and is a private not for profit organization who's mission is to improve the quality of health care. NCQA is known as a principal organization that leads improvement in the health care system and facilitates the recognition of the topic of health care quality throughout the country.
- NCQA works with large employers, policy makers, health care providers, Health Plans, and patients to develop
 agreement around crucial health care quality concerns to determine what is important, how to measure it, and how to
 advocate for changes for the better.
- HEDIS stands for Healthcare Effectiveness Data and Information Set.
- The first set of HEDIS measures came out in 1993 as HEDIS 2.0. The release of these measures marked the first
 time that organizations were held accountable for accomplishing valuable measurable outcomes. Health care as a
 whole has benefited from the continued use of these measures as quality benchmarks that promote continuously
 evolving quality improvement and as a result continuous improvements in the care provided.



- It is a tool that is used by more than 90% of Health Plans to determine execution of the aspects of care and service.
 The measures that are used are very specific and well defined so that plans can be measured equally against each other.
- Since the data is so widely collected, the results from HEDIS are also used by health plans for internal quality improvement.
- HEDIS data is used by a wide variety of people including employers, consumers, consultants, purchasers, etc. combined with accreditation information in order to choose a health plan.
- The measurement set for HEDIS is evaluated and changes are implemented each year as needed. The measures are
 looked at by NCQA's Committee on Performance Measurement which is composed of a broad based group
 representing employers, consumers, health plans, health care providers, and others. This group deliberates and selects
 the HEDIS measures that will be included and field tests decide how it gets measured.
- To make sure that the HEDIS results are valid, all data submitted are thoroughly audited by certified auditors using a process created by NCQA.



- Health data is collected throughout the year with a more focused HEDIS Data Collection ("Chart Chases") conducted between January and June. Annual reports are published in July.
- Scores from HEDIS impact the Health Insurance Plan Rankings, directly effect health plan accreditation operation, and are used by some states to decide on Medicaid incentives and sanctions.
- The HEDIS Measures of Care focus on a large assortment of health concerns such as: Appropriate antibiotic use;
 Asthma; Breast, cervical and colorectal cancers; Cardiovascular disease; Care for older adults;
 Childhood and adolescent immunizations; COPD; Diabetes; High blood pressure; Hospital readmissions;
 Medication management; Mental illness; Prenatal and postpartum care; Smoking; Weight assessment
 Patient experience (CAHPS); Vaccinations for adults and older adults (CAHPS).
- HEDIS includes the Consumer Assessment of Healthcare Providers and Systems (CAHPS) survey which assesses the members encounters with their health care in areas like clinician communication and getting needed care quickly. The member then rates their health plan on a scale of 0-10.

Domains



HEDIS 2018 looked at the care provision across body systems; prevention and screening; access to and satisfaction
with the provision of healthcare services; and measures usage of certain procedures and settings of care.

#Measures

HEDIS 2018 was divided into seven domains:

 Effectiveness of Care 	55(11 Hybrid)
Access/Availability of Care	6(1 Hybrid)
Experience of Care	3
Utilization & Risk Adjusted Utilization	15(4 Hybrid)
Relative Resource Use	5
Health Plan Descriptive Information	6
Measures Collected using Electronic Clinical Data Systems	5

HEDIS: Definitions



- Collection and Reporting Method: Four Ways Data is collected:
- * Administrative: Medical, pharmacy, and encounter claims.
- Hybrid: Medical and pharmacy claims, encounters and medical record data.
- Survey: Consumer Assessment of Healthcare Providers and Systems (CAPHS).
- Electronic Clinical Data Systems: EMR or Health Information Network.
- Measurement Year: In most cases, the measurement year is the 12-month timeframe between which a service was rendered, and generally runs Jan. 1 through Dec. 31. Data collected from this timeframe is reported during the reporting year.

HEDIS: Definitions



- **Reporting Year:** The reporting year is the timeframe when data is collected and reported. The data is from the measurement year, which is usually the year prior or can be or up to 5 years.
 - **Example:** The 2018 reporting year would include a review of data from services rendered during the measurement year, which would be 2017 and/or any time prior. Reporting year data would likely be released in June 2018, depending on the measure.
- **HEDIS Numerator:** The number of members who meet the eligibility criteria based on NCQA technical specifications and receive the appropriate care, treatment or service.
- **HEDIS Denominator:** The number of members who qualify for the measure criteria, based on NCQA technical specifications.
- **Medical Record Data:** This is the information taken directly from a member's medical record to validate services rendered that weren't captured through claims, encounters or supplemental data.

EP 3 Guidelines



Quick Reference Charts for the Classification and Stepwise Treatment of Asthma (Adapted from 2007 NHJB Quidelines for the Diagnosis and Treatment of Asthma Expert Panel Report 5)

Adhers CREET is the degree to definite it between the relief process and delates which step to ideals between Adhers CREET is the degree to definite by and in the step on the page, proced proper process consistent and control process. The classification of a descript process of creates in beat of the control process of control process. As the classification of the classif

				Classification of Asthma SEVERITY (Intermittent vs. Persistent)			
Components of SEVERITY		nents of SEVERITY (Yours)		Persistent			
	-	(1000)	Intermittent	Mild	Moderate	Severe	
\neg	Symptoms	All	≤2 days/week	> 2 days/week but not daily	Daily	Throughout the day	
	Nightlime awakenings	0-4	0	1-2s/month	3-4s/north	> 1s/week	
		≥ 5	≤ 2s/month	3-Aximonth	> 1s/week but not nightly	Often Tylweek	
E	SABA use for symptom control	All	≤2 days/week	> 2 days/week but not daily	Daily	Several times a day	
The second	interference with normal activity	All	None	Minor limitation	Some limitation	Extremely limited	
Ξ	Lung function:						
	FEV, (predicted) or PEF (personal best)	≥5	Normal FEV: between exacerbations > 80%	> 80%	60-80%	< 60%	
	FEV,FVC	5-11	> 85%	>80%	75-80%	< 60%	
		≥ 12	Normal	Normal	Reduced 5%	Reduced > 5%	
\neg	Exacerbations	0-4		≥ 2r in 6 moreties or ≥ 4 whereging episodes/verar leading > 1 day AND risk f			
SP.	requiring oral	5-11	s falver		≥ 2slyeer		
Œ	corticusteroids 8 1xl		S TAYON	Consider severity and interval since last exponention. Frequency and severity may flucture for patients in any severity category. Relative annual risk of exportations may be related.			
Reci	ommended step for	0-4				Step 3	
starting treatment."		5-11	Slep 1	Step 2	Simp 3	Step 3 or 4	
		≥ 12				Step 4 or 5	
		All				of and conficultaroids	
		All		evaluate level of authors control that			
-			For children 0-4 years old, if no clear	benefit is observed in 4-8 weeks, sto	p teatment and consider alternative	e diagnosis or adjusting therep	

n	omponents of CONTROL	Age		Level of Asthma CONTROL		
u	III DOMENS OF CONTROL	(Yours)	Well Controlled	Not Well Controlled	Very Poorty Controlled	
T	Symptoms	0-4 5-11	≤2 days/week but ≤1 siday	> 2 days/week or multiple times on < 2 days/week	Throughout the day	
- 1		≥ 12	≤2 days/week	> 2 days/week		
- [Nighttime awakenings	0-4	s falmouth	> txinorth	> tylveck	
- 1		5-11	S tomown	≥ 2s/month	≥ 2ulweek	
- 1		≥ 12	≤2dnorth	1-3dweek	≥ 4c/week	
	Interference with normal activity	All	None	Some limitation	Extremely limited	
	SABA use for symptoms	All	≤2 days/week	> 2 days/week	Several times per day	
r i	Lung function					
-	FEV, (predicted) or PEF (personal best)	≥5	>80%	60-80%	< 60%	
- [FEWFVC	5-11	> 80%	75-80%	<79%	
	Validated questionnaires					
- 1	ATAQ	≥ 12	Ó	1-2	34	
- [ACQ	≥ 12	≤0.75	215	nis	
_[ACT	≥12	≥ 20	16-19	≤15	
	Exacerbations requiring	0-4		2-3slyeer	>3dyner	
- [oral corticosteroids	5-11 ≥12	≤ 1 slyeer	dyear evel since lest execerbation		
	Reduction in lung growth	5-11		Evaluation requires long-term follow-up care		
	Loss of lung function	≥12		Evaluation requires long-term follow-up care		
	Treatment-related adverse effects	Medication side		fects can vary in intensity from mone to very trout	blesome and worrisome.	
Recommended treatment actions				Step up 1 step	Step up 1-2 steps and consider short course of onal conticesteroid	
		All	Maintain current step; regular follow-up at every 1–6 months; consider stepping down If well controlled for > 3 months		timent option was used in a step, discontinue a realment for that step.	
				Reevaluate the level of asthms control in	2-6 weeks and adjust therapy accordingly.	
				For side effects, consider alternative treatment options.		

Stepwise Approach for Managing Asthma Long Term

		CARL HILLSON HARRIST	ASSESS	COMISOL	d, and complet condition	'
	_	Ship 0(0)	N if possible (and asthma)		Bin (rife)	
						Step 6
					Step 5	
				Step 4		
			Step 3	Supr		
		Store 2	sieh a			
		Step 2				
	Step 1					
	Intermittent Asthma	Core		astert Asthma: Daily Medic teo 3 care or higher is require	ation ed. Consider consultation at a	tro 2
Preferred	SABA as needed	Low-dose ICS	Medium-dose ICS	Medium-dose ICS	High-dose ICS	High-dose ICS
				•		•
				LASA of montelulast	LASA of mortelulast	Onel confecutaroids
						LABA of montelulant
Atternative		Cromoker of mortelulast				Dana II diama
			education and environment	al control at each step.		
Rescue	SABA as readed for syr	optoms. Treatment intensity o	depends on symptom severity			
Medication		rptoms, SABA every 4-6 hox				
		oral confecularcids if exaces			exportations.	
	 Frequent or increasing a 	se of SABA may indicate ins	dequate control and the need	to step up treatment.		
	Interrettent Asthrop			istert Asthma: Daily Medic		
	I HATTER ASSITE	Core	sult with eathree specialist if a	tep 4 care or higher is require	ed. Consider consultation at a	dap 3.
Preferred	SABA as needed	Low-dose ICS	Low-dose ICS	Medium-dose ICS	High-dose ICS	High-dose ICS
			+ LABA, LTRA, or	LABA	LABA	LABA
			Theophyline	LAGA	LACA	LADA
						Oral conformateroids
Atternative		Cromolyn, LTRA.	OR .	Wedura-dose ICS	High-dose ICS	High-done ICS
		Nedrozonii, ar		•		
		Thosphyline	Medium-dose ICS	LTRA of Theophyline	LTRA or Theophyline	LTRA or Theophyline
						*
						Oral confocutaroids
			fronmental control, and ma taneous allergen immunother			
Descrip	. CADA on resolut for the	optoms - up to 3 treatments				
Medication	Consider short course of		a common many	. I commercial control of the control	or symptom severy.	
			rptom relief (not prevention o	(EB) generally indicates ins	dequate control and the need	to step up treatment.
				isteri Asthma: Daily Medic		
	Intermittent Asthma	Core			ed. Consider consultation at a	teo 3.
Preferred	SABA as needed	Low-dose ICS	Low-dose ICS	Medium-dose ICS	High-dose ICS	High-dose ICS
			•	•		
			LABA	LABA	LABA	LABA
			OR			•
			Medium-dose ICS			Oral confocutaroid
					Consider Orealizameb for	Consider Omelizumeb for
Alternative		Country LTDA				patients who have allergic
Alternative		Cromolyn, LTRA, Nedrocromil, Of	Low-dose ICS	Medium-dose ICS		
Alternative		Cromolyn, LTRA, Nedrocromil, or Theophyline	Low-dose ICS +	•	patients who have allergic anthrea	siting
Alternative		Nedrozonii, ar		Medium-dose ICS * LTRA, Theophyline, df Zileuton	petients who have allergic	
Alternative		Nedrocromil, or Theophyline Patient education and env	Low-dose ICS + LTRA, Theophyline, or Zileuton frommental control, and ma	+ LTRA, Theophyline, ar Zileuton rangement of comorbidities	patients who have allergic authors at each step.	
		Nedrocrossi, or Theophyline Patient education and envision 24: Consider subcut	Low-dose ICS LTRA, Theophyline, IF Zileuton frommental control, and ma amous silengen immunithen	* LTRA, Theophyline, or Zieuton ragement of comorbidities may for pelients who have all	patients who have allergic actives at each step. egic actives.	
Rescue		Nedrozronii, or Theophylline Patient education and env Step 2-4: Consider subcut optoms – up to 3 treatments :	Low-dose ICS LTRA, Theophyline, IF Zileuton frommental control, and ma amous silengen immunithen	* LTRA, Theophyline, or Zieuton ragement of comorbidities may for pelients who have all	patients who have allergic actives at each step. egic actives.	
	 Consider short course of 	Nedrocrossi, or Theophyline Patient education and env Step 2-4: Consider subcut sploms – up to 3 treatments of oral conficenteroids.	Low-dose ICS * LTRA, Theophyline, or Zileaton frommertial control, and ma terecus dilengen immunohen at 20-minute intervals initially	LTRA, Theophyline, or Zieuton rangement of comorbidities spy for patients who have allo Treatment intensity depends	patients who have allergic actives at each step. argic anthres. on symptom severity.	atima
Rescue Medication	Consider short course or Increasing use of SASA	Nedrocroesi, or Theophyline Patient education and ensisting 2-4: Consider subout optoms – up to 3 treatments of oral corticosteroids. or use > 2 days/week for syn	Low-dose ICS * LTRA, Theophylline, or Zileaton fronmental confirol, and ma areasa silengen immuniform at 20-minute intervets initially reptom relief (not prevention or	a LTRA, Theophyline, or Zhadon reagement of comorbidities up to patients who have all Treatment intensity depends of EIO generally indicates into	petients who have allergic actives at each step, egic authors, a on symptom severity, dequate control and the need	atima
Rescue	Consider short course or Increasing use of SASA If an alternative treatment	Nedrocrossi, of Theophyline Patient education and envision 2-4: Consider subout representation on the control of control corticosteroids. or use > 2 depulsees for synits used and response is fee	Low-doe ICS * LTRA, Theophyline, IZ Zileuton frommental control, and ma amenas allergen immunother at 20-minute intervals initially reptom relief (not prevention o adequate, discontinue it and	LTRA, Theophylline, or Zindon raggement of comorbidities spy for patients who have all Treatment intensity depend of EID) generally indicates in see the preferred treatment b	petients who have allergic actives at each step, egic authors, a on symptom severity, dequate control and the need	atima
Rescue Medication	Consider short course or Increasing use of SABA If an alternative treatme Theophyläne requires se	Nedrocroesi, or Theophyline Patient education and ensisting 2-4: Consider subout optoms – up to 3 treatments of oral corticosteroids. or use > 2 days/week for syn	Low-dose ICS * LTRA, Theophyline, or Zileaton frommental control, and ma tences allergen immunotion at 20-minute intervals initially implomented (not prevention o entiring zileaton requires live	a LTRA, Theophyline, or Zinadon progresst of comorbidities apy for patients who have all Treatment intensity depend of EI(6) generally indicates in an the preferred breatment by a function monitoring.	petients who have allergic actives at each step, egic authors, a on symptom severity, dequate control and the need	atima


For usual designs of asthma medications, refer to pages 46-52 of the EFR-3 Summary Deport 2007 (NEP publication Number 85-546). The full guidelines, summary report, evidence takins, and this is other released several medication on the NFLS design and the several report of several report of the several repo

The information in this reference was reviewed by the 1945 Author Quality trapscenter (theolog Constitute and was build published on 900000000, Question and or connection ray be disclosed Article (g., Phantil) prolonging

FEV, forced equatory volume in 1 around, PVC, forced that separate PEF, peak explosiony force 3/644, which exting between principles.

GIST Model





HEDIS Asthma Measures



- Appropriate staging and classification of asthma is very important. Physicians need to utilize the Stepwise Approach
 to Managing Asthma using the GIST (Guideline Implementation Steps and Tools) tool or the EP3 Guidelines.
- Definition of Persistent Asthma.
- Patients are identified as having met at least one (1) of the following criteria during **both** the measurement year and the prior year. The criteria need not be the same in both years:
 - At least one ED visit with asthma as the principal diagnosis.
 - At least one acute inpatient encounter with asthma as the principal diagnosis.
 - At least four (4) outpatient asthma visits on different dates of service, with asthma as one of the listed diagnosis and at least two (2) asthma medication dispensing events rescue and/or controller medication.
 - At least four (4) asthma medication dispensing events rescue and/or controller asthma medication.

CPT Codes for All Asthma Measures



- Codes:
- J45.20-J45.22
- J45-30-J45.32
- J45.40-J45.42
- J45.50-J45.52
- J45.990
- J45.991
- J45.909, J45.998
- J45.901-J45.902
- Extrinsic & Intrinsic Asthma
- Exercise Induced
- Bronchospasm
- Cough Variant Asthma
- Asthma NOS



- Measure: AMR
- Definition: Percentage of members ages 5–64 who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during the measurement year.
- Plan(s) Affected:
 - Commercial
 - Medicaid
- Quality Program(s) Affected:
 - NCQA Accreditation
- Collection and Reporting Method:
 - Administrative

Claim/Encounter Data and Pharmacy Data

 Medications: To comply with this measure, a member must have the appropriate ratio of controller medications to total asthma medications. Providers need to check the Michigan MDHHS Medicaid Health Plan Common Formulary for covered asthma medications.



Asthma Controller Medications:

• Inhaled Corticosteroids (**preferred**), Inhaled steroid combinations, Mast cell stabilizers, Methylxanthines Antibody Inhibitor, Antiasthmatic combinations, Leukotriene modifiers.

Drug Category	Medications	
Antiasthmatic combinations	 Dyphylline- guaifenesin 	Guaifenesin- theophylline
Antibody inhibitors	Omalizumab	
Anti-interleukin-5 antibody therapies	Mepolizumab	Reslizumab
Inhaled corticosteroids	BeclomethasoneBudesonideCiclesonide	Flunisolide Fluticasone CFCfree Mometasone
Inhaled steroid combinations	Budesonide- formoterolFluticasone- salmeterol	 Fluticasone-vilanterol Mometasone- formoterol
Leukotriene modifiers	MontelukastZafirlukast	• Zileuton
Mast cell stabilizers	• Cromolyn	
Methylxanthines	 Dyphylline 	Theophylline



Asthma Reliever Medications

Drug Category	Medications	
Short-acting, inhaled beta-2 agonists	AlbuterolLevalbuterol	 Pirbuterol



• Exclusion(s): If applicable, see Appendix for codes and descriptions.

	Exclusions Timeframe	
ı	Members who use hospice services or elect to use a nospice benefit, regardless of when the services began in the measurement year	Any time during the measurement year
•	Acute respiratory failure	Any time during a member's history through Dec. 31 of
•	Chronic obstructive pulmonary disease	the measurement year
•	Chronic respiratory conditions due	
	to fumes/vapors	
•	Cystic fibrosis	
•	Emphysema	
•	Obstructive chronic bronchitis	
	Members who weren't prescribed an asthma controller medication	Any time during the measurement year



- Measure: MMA
- Definition: Percentage of members ages 5–64 during the measurement year who were identified as having persistent asthma and were dispensed appropriate medications that they remained on during the treatment period.
- Two rates are reported:
 - 1. Percentage of members who remained on an asthma controller medication for at least 50 percent of the treatment period.
 - 2. Percentage of members who remained on an asthma controller medication for at least 75 percent of the treatment period.
- The treatment period is the timeframe between the date of the earliest prescription for any asthma controller medication during the measurement year through the end of the measurement year.



- Plan(s) Affected
 - Commercial
 - Medicaid
- Quality Program(s) Affected
 - CMS Quality Rating System
 - NCQA Accreditation (75 percent of treatment period only)
- Collection and Reporting Method
 - Administrative
 Claim/Encounter Data and Pharmacy Data
- Medications: To comply with this measure, a member must have remained on one of the following asthma controller medications for the required duration of time. Providers need to check the Michigan MDHHS Medicaid Health Plan Common Formulary for covered asthma medications.



Asthma Controller Medications:

• Inhaled Corticosteroids (preferred), Inhaled steroid combinations, Mast cell stabilizers, Methylxanthines Antibody Inhibitor, Antiasthmatic combinations, Leukotriene modifiers.

Drug Category	Medications	
Antiasthmatic combinations	Dyphylline- guaifenesin	Guaifenesin- theophylline
Antibody inhibitors	Omalizumab	
Anti-interleukin-5 antibody therapies	 Mepolizumab 	Reslizumab
Inhaled corticosteroids	BeclomethasoneBudesonideCiclesonide	Flunisolide Fluticasone CFCfree Mometasone
Inhaled steroid combinations	Budesonide- formoterolFluticasone- salmeterol	Fluticasone-vilanterolMometasone- formoterol
Leukotriene modifiers	Montelukast Zafirlukast	• Zileuton
Mast cell stabilizers	• Cromolyn	
Methylxanthines	 Dyphylline 	 Theophylline



Exclusion(s)

If applicable, see Appendix for codes and descriptions.

E	xclusion Timeframe	
h	Members who use hospice services or elect to use a cospice benefit, regardless of when the services began during the measurement year	Any time during the measurement year
•	Acute respiratory failure Chronic obstructive pulmonary disease Chronic respiratory conditions	Any time during a member's history through Dec. 31 of the measurement year
•	due to fumes/vapors	
•	Cystic fibrosis	
•	Emphysema Obstructive chronic bronchitis	
	Members who weren't prescribed an asthma controller medication	Any time during the measurement year

Physician Management of Asthma to Best Meet HEDIS Measures



- Prescribe a long term "control" medication as well as a short term "rescue" inhaler.
- Educate the patient on the use of all asthma medications and stress the importance of taking "control" medication daily.
- Schedule an office visit after any ER or inpatient stay to ensure the patient has both "rescue" and "control" asthma medications.
- Schedule frequent office visits for asthma follow up care, to monitor asthma control, and to evaluate asthma medication utilization.
- Ensure all asthma patients have an Asthma Action Plan.
- Monitor the use of "rescue" asthma medications at all office visits. The majority of patients over 30 are placed into the measure due to frequent (four or more) fills of "rescue" asthma medications.
- * Educate all office staff on the difference between "control" and "rescue" asthma medications.
- Sample control medications are discouraged. If they are given, document date given, medication name, and dosage in patient chart.
- Perform spirometry test to confirm asthma diagnosis vs. chronic obstructive lung disease.

Helpful MDHHS Webpages



- MDHHS HEDIS Results: Statewide Aggregate Reports:
- https://www.michigan.gov/mdhhs/0,5885,7-339-71547_4860_78446_78576-39268--,00.html
- MDHHS Medicaid Health Plan Information Page :
- https://www.michigan.gov/mdhhs/0,5885,7-339-71551_2945_42542_42544_42644-150910--,00.html



